Many peptides reduce insulin resistance, stabilizing glucose levels and reducing fat storage
The time to therapeutic effect varies among medications, with initial glucose improvements visible within 2 weeks for both drugs
After the expiration date, semaglutide may lose potency, which can lead to subtherapeutic dosing
A considerable proportion is excreted in unchanged form and another in the form of conjugated metabolites
All four rows describe patients with type 2 diabetes at high cardiovascular risk, namely LEADER, SUSTAIN-6, PIONEER 6, and REWIND, with the REWIND row also noting reduced major adverse cardiac events
During the item generation and discussion and clarification phases, the experts identified 14 distinct challenges: costs, supply challenges, lack of evidence, polypharmacy, barriers to prescription, lack of knowledge, adherence concerns, aversion to injection therapy, clinical inertia, titration needs, perceived health state, fear of adverse effects, lack of clinical guideline recommendations, and lack of measurable outcomes to guide therapy
